Congress Materials – Society for Investigative Dermatology (SID 2026)
2026 Society For Investigative Dermatology | May 13-16 | Chicago, IL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Reduction of Skin CD8 TRMs in Icotrokinra-Treated Participants With Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Results Through Week 52
J Angsana, Y Ren, J Sendecki, K Kohler, N Roscoe, J Gooco, C Sisk, T Lee, C DeKlotz, M Miller-Kassamali, J Cafone, P Newbold, A Kannan, ME Polak, D Waterworth, N Sabins, C Cuff, K Eyerich, K Wolk, R Sabat, H Mehta, M Sarfati, S Molin, R Bissonnette
This document will be available on May 14 2026
SPECTREM: Guselkumab lowers disease-related serum cytokines in low BSA, moderate psoriasis with high-impact sites
Elizabeth Chen, Philip Cooper, Shawn Kwatra, Raymond Jaihyun Cho, George Han, Aaron Farberg, Theodore Alkousakis, Rohit Panchakshari
This document will be available on May 14th 2026
VISIBLE: multiplex Immunofluorescence (mIF) and Melanocyte Transcriptomic Analyses of Psoriasis (PsO) in Skin of Color
JE Hawkes, B Ungar, J Talia, G Han, A Farberg, SG Kwatra, R Cho, C-H Chou, A Liu, E Chen, Y Chen, L Barnett, R Panchakshari, T Alkousakis, J North
This document will be available on May 14 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.